Premium
Protective effect of peroxisome proliferator activated receptor gamma agonists on diabetic and non‐diabetic renal diseases
Author(s) -
CHUNG BYUNG HA,
LIM SUN WOO,
AHN KYUNG OHK,
SUGAWARA AKIRA,
ITO SADAYOSHI,
CHOI BUM SOON,
KIM YONG SOO,
BANG BYUNG KEE,
YANG CHUL WOO
Publication year - 2005
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1111/j.1440-1797.2005.00456.x
Subject(s) - medicine , peroxisome proliferator activated receptor , receptor , peroxisome proliferator , peroxisome proliferator activated receptor gamma , pharmacology , diabetes mellitus , endocrinology
SUMMARY: Peroxisome proliferator activated receptor gamma (PPARγ) agonist has not only antidiabetic effect but also a protective effect against various types of injury of the kidney. The protective effects of PPARγ agonists are observed in diabetic nephropathy and non‐diabetic renal diseases such as 5/6 ablation model of renal failure, experimental glomerulonephritis, ischemia‐reperfusion injury, hypertensive nephropathy and cyclosporin‐induced renal injury. The mechanism of renoprotection by PPARγ agonist is multifactorial. Anti‐fibrotic and anti‐inflammatory effects, suppression of renin‐angiotensin system, vascular protective effect and antiapoptotic effect were proposed.